Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population

Table 2 Clinical biochemical characteristics of non-alcoholic fatty liver disease and controls

	Lean-NAFLD		Overweight-obese-NAFLD		P value
	Controls	NAFLD	Controls	NAFLD
FBG (mmol/L)	5.30 ± 1.36	5.91 ± 1.85a	5.52 ± 1.31b	5.76 ± 1.42a	< 0.01
Fasting insulin (IU/mL)	6.42 ± 3.76	8.27 ± 3.93a	7.28 ± 4.33	10.84 ± 5.28ac	< 0.01
HOMA-IR	1.55 ± 0.97	2.16 ± 1.42a	1.87 ± 1.35b	2.73 ± 1.53ac	< 0.01
TC (mmol/L)	4.86 ± 0.93	5.20 ± 1.01a	5.00 ± 0.90b	5.10 ± 0.92	< 0.01
TG (mmol/L)	1.18 ± 1.13	1.71 ± 1.23a	1.40 ± 1.01b	1.83 ± 1.19a	< 0.01
HDL-C (mmol/L)	1.58 ± 0.35	1.45 ± 0.30a	1.44 ± 0.30b	1.35 ± 0.27ac	< 0.01
LDL-C (mmol/L)	2.90 ± 0.79	3.12 ± 0.78a	3.09 ± 0.77b	3.13 ± 0.78	< 0.01
ALT (U/L)	18.32 ± 13.85	21.61 ± 11.92a	21.10 ± 16.13b	27.23 ± 18.25ac	< 0.01
AST (U/L)	19.27 ± 6.85	21.07 ± 9.26a	20.23 ± 11.10	22.37 ± 9.87a	< 0.01
ALP (U/L)	64.34 ± 18.16	71.96 ± 20.49a	66.94 ± 21.26	70.00 ± 18.47a	< 0.01
GGT (U/L)	26.11 ± 27.99	35.76 ± 34.92a	33.42 ± 33.95b	47.26 ± 48.44ac	< 0.01
UA (μmol/L)	280.04 ± 82.31	303.30 ± 86.72a	307.59 ± 85.54b	340.60 ± 92.68ac	< 0.01
BUN (mmol/L)	5.00 ± 1.24	5.15 ± 1.25	5.16 ± 1.19	5.14 ± 1.24	0.15
CRE (μmol/L)	69.26 ± 14.37	70.34 ± 13.84	71.72 ± 14.18b	74.53 ± 14.48c	< 0.01

^aP < 0.05 vs control in same weight group;

^bP < 0.05 vs Lean-control group;

^cP < 0.05 vs Lean-NAFLD group. NAFLD: Non-alcoholic fatty liver disease; FBG: Fasting blood glucose; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transferase; UA: Serum uric acid; BUN: Blood urea nitrogen; CRE: Serum creatinine.